GO:0035674 tricarboxylic acid transmembrane transport: Mitochondrial Metabolism Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035674 (tricarboxylic acid transmembrane transport) is the biological process by which tricarboxylic acid (TCA) cycle intermediates are moved across cellular membranes.
• The process is essential for mitochondrial energy production, cytosolic substrate supply, and inter-organelle metabolic communication.
• Key transporters include the mitochondrial pyruvate carrier (MPC) for pyruvate and SLC13 family sodium-carboxylate transporters for citrate, succinate, and other TCA intermediates.
• Dysregulation of tricarboxylic acid transmembrane transport is linked to cancer metabolic reprogramming, Parkinson's disease, cystic fibrosis, and nephrolithiasis.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of transporter function in health and disease.
• Understanding this process supports therapeutic strategies targeting mitochondrial metabolism and immunometabolism.
Description
Tricarboxylic acid transmembrane transport (GO:0035674) is the process in which a tricarboxylic acid is transported across a membrane. Tricarboxylic acids, including citrate, isocitrate, alpha-ketoglutarate, succinate, fumarate, and malate, are central intermediates of the TCA cycle and key signaling molecules. Their movement across the mitochondrial inner membrane, plasma membrane, and other cellular membranes is mediated by specific carrier proteins and is essential for energy production, biosynthesis, and metabolic signaling. This process is fundamental to mitochondrial function and cellular metabolism, and its dysregulation contributes to a range of human diseases, including cancer, neurodegeneration, and metabolic disorders. Researchers study tricarboxylic acid transmembrane transport to understand how cells adapt to metabolic stress, how mitochondria communicate with other organelles, and how to target these pathways therapeutically.
tricarboxylic acid transmembrane transport At A Glance
| GO ID | GO:0035674 |
|---|---|
| GO term | tricarboxylic acid transmembrane transport |
| Ontology | biological_process |
| Synonym | tricarboxylic acid membrane transport |
| Definition | The process in which a tricarboxylic acid is transported across a membrane. |
| Major function | Movement of TCA cycle intermediates across cellular membranes for energy production, biosynthesis, and signaling. |
| Key transporters | Mitochondrial pyruvate carrier (MPC), SLC13 family sodium-carboxylate transporters, and other carrier proteins. |
| Associated diseases | Cancer, Parkinson's disease, cystic fibrosis, nephrolithiasis, inflammatory diseases. |
| Research methods | CRISPR knockout/knock-in, metabolic flux analysis, proteomics, imaging, and transporter-specific assays. |
What Is GO:0035674?
According to the Gene Ontology, tricarboxylic acid transmembrane transport (GO:0035674) is defined as the process in which a tricarboxylic acid is transported across a membrane. This biological process encompasses the directed movement of any tricarboxylic acid molecule, such as citrate, isocitrate, alpha-ketoglutarate, succinate, fumarate, or malate, from one side of a membrane to the other. It includes transport across the mitochondrial inner membrane, the plasma membrane, and other cellular membranes, and is typically mediated by specific membrane transporter proteins.
Why Is tricarboxylic acid transmembrane transport Important in Cell Biology?
Tricarboxylic acid transmembrane transport is critical for maintaining cellular energy homeostasis, providing substrates for biosynthesis, and enabling metabolic communication between organelles. It supports mitochondrial oxidative phosphorylation by supplying pyruvate and other TCA cycle intermediates, and it facilitates cytosolic processes such as gluconeogenesis and fatty acid synthesis. Dysregulation of this transport is implicated in cancer metabolic reprogramming, neurodegeneration, and inflammatory diseases, making it a key area for therapeutic intervention.
• Supplies pyruvate to mitochondria for oxidative phosphorylation and TCA cycle function.
• Enables cytosolic citrate transport for fatty acid and cholesterol synthesis.
• Regulates metabolic signaling through succinate, itaconate, and other TCA intermediates.
• Supports mitochondrial fitness and dopamine-iron homeostasis in Parkinson's disease models.
• Modulates cystic fibrosis transmembrane conductance regulator (CFTR) function via citrate transport.
• Contributes to nephrolithiasis risk in cystic fibrosis patients through altered citrate handling.
• Plays a role in cancer cell metabolic reprogramming and mitochondrial-lysosome contact sites.
• Provides targets for immunometabolism and anti-inflammatory therapies.
• Essential for understanding mitochondrial pyruvate carrier structure and mechanism.
• Facilitates sodium-coupled carboxylate transport in human physiology and disease.
What Happens During tricarboxylic acid transmembrane transport?
Substrate recognition and binding at the membrane
In simple terms: The transporter grabs the TCA molecule on one side of the membrane.
Tricarboxylic acid transmembrane transport begins with the specific recognition and binding of a tricarboxylic acid substrate, such as pyruvate, citrate, or succinate, by a membrane-embedded transporter protein. For example, the human mitochondrial pyruvate carrier (MPC) binds pyruvate with high specificity to initiate its transport into the mitochondrial matrix. Similarly, SLC13 family transporters recognize sodium ions and carboxylate substrates to mediate coupled transport.
Conformational change and translocation across the membrane
In simple terms: The transporter changes shape to move the molecule through the membrane.
Upon substrate binding, the transporter undergoes conformational changes that allow the tricarboxylic acid to pass through the membrane. Structural studies of the human mitochondrial pyruvate carrier reveal a mechanism involving alternating access, where the protein shifts between outward-facing and inward-facing states to translocate pyruvate. This process may be driven by electrochemical gradients, such as the sodium gradient used by SLC13 transporters.
Release of the substrate on the opposite side
In simple terms: The molecule is released inside the target compartment.
After translocation, the tricarboxylic acid is released into the target compartment, such as the mitochondrial matrix or the cytosol. This release is essential for subsequent metabolic reactions, including the TCA cycle, gluconeogenesis, and fatty acid synthesis. The directionality and efficiency of release can be influenced by substrate concentration gradients and membrane potential.
Coupling to energy and metabolic pathways
In simple terms: The transported molecule feeds into energy production and building blocks.
Once inside the target compartment, tricarboxylic acids participate in core metabolic pathways. Pyruvate is converted to acetyl-CoA to fuel the TCA cycle and oxidative phosphorylation. Citrate can be exported to the cytosol for fatty acid and cholesterol synthesis, a process linked to mitochondrial-lysosome contact sites and cholesterol export. Succinate and itaconate can act as signaling molecules in immunometabolism.
Regulation by cellular metabolic state
In simple terms: The cell adjusts transport based on its energy needs.
Tricarboxylic acid transmembrane transport is regulated by the cellular metabolic state, including energy charge, substrate availability, and hormonal signals. For instance, dopamine-iron homeostasis interactions can rescue mitochondrial fitness by modulating transport and metabolism in Parkinson's disease models. In cystic fibrosis, citrate transport can be altered, affecting CFTR function and nephrolithiasis risk.
Key Genes Involved in GO:0035674 tricarboxylic acid transmembrane transport
The following genes and proteins are key mediators or regulators of tricarboxylic acid transmembrane transport, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MPC1 | Mitochondrial pyruvate carrier subunit; mediates pyruvate transport into mitochondria | Structural and functional studies of pyruvate transport; target for metabolic diseases |
| MPC2 | Mitochondrial pyruvate carrier subunit; essential for pyruvate uptake | Knockout models show impaired mitochondrial metabolism |
| SLC13A1 | Sodium-dependent sulfate/carboxylate transporter | Renal and intestinal transport of TCA intermediates |
| SLC13A2 | Sodium-dependent citrate transporter | Citrate transport in liver and kidney; linked to metabolic disorders |
| SLC13A3 | Sodium-dependent dicarboxylate transporter | Transport of succinate, alpha-ketoglutarate; implicated in cancer |
| SLC13A4 | Sodium-dependent sulfate transporter | Placental and neuronal transport; potential disease links |
| SLC13A5 | Sodium-dependent citrate transporter | Citrate transport in neurons; mutations cause epilepsy |
| SLC25A1 | Mitochondrial citrate carrier | Citrate export for cytosolic fatty acid synthesis |
| SLC25A10 | Mitochondrial dicarboxylate carrier | Transport of malate, succinate; role in gluconeogenesis |
| SLC25A11 | Mitochondrial alpha-ketoglutarate/malate carrier | TCA cycle intermediate exchange |
| SLC25A12 | Mitochondrial aspartate/glutamate carrier | Indirectly supports TCA cycle and transport |
| SLC25A13 | Mitochondrial aspartate/glutamate carrier | Citrin deficiency; linked to metabolic disorders |
| TM4SF5 | Tetraspanin; regulates mitochondrial-lysosome contact sites and cholesterol export | Cancer metabolism and glucose-mediated reprogramming |
| IRG1 | Immune-responsive gene 1; produces itaconate from cis-aconitate | Immunometabolism and inflammatory diseases |
| CFTR | Cystic fibrosis transmembrane conductance regulator | Citrate transport affects CFTR function; nephrolithiasis risk |
| Dopamine receptor genes | Modulate dopamine-iron homeostasis and mitochondrial fitness | Parkinson's disease models |
| ATP synthase | Uses proton gradient generated by TCA cycle to synthesize ATP | Decarboxylation phosphorylation and energy production |
How Is tricarboxylic acid transmembrane transport Regulated?
Tricarboxylic acid transmembrane transport is regulated at multiple levels, including transcriptional control of transporter genes, post-translational modifications, and allosteric regulation by metabolic intermediates. The process is influenced by cellular energy status, oxygen availability, and hormonal signals. For example, glucose-mediated mitochondrial reprogramming by cholesterol export at TM4SF5-enriched mitochondria-lysosome contact sites modulates transport and metabolism. Dopamine-iron homeostasis interactions can rescue mitochondrial fitness by affecting transport in Parkinson's disease models. Additionally, the IRG1-itaconate axis regulates immunometabolism and inflammatory responses, indirectly influencing TCA intermediate transport. Sodium-carboxylate transporters of the SLC13 family are regulated by sodium gradients and substrate availability.
tricarboxylic acid transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TM4SF5 | Cancer metabolic reprogramming | Knockout and overexpression in cancer cell lines |
| SLC13A5 | Epilepsy, neurological disorders | Point mutation knock-in in neurons |
| CFTR | Cystic fibrosis, nephrolithiasis | ΔF508-CFTR knock-in models treated with citrate |
| MPC1/MPC2 | Metabolic disorders, cancer | Knockout in cancer and metabolic cell lines |
| IRG1 | Inflammatory diseases | Knockout and overexpression in macrophages |
Cancer metabolic reprogramming
Altered tricarboxylic acid transmembrane transport supports cancer cell metabolic reprogramming. TM4SF5-enriched mitochondria-lysosome contact sites mediate cholesterol export and glucose-mediated mitochondrial reprogramming, promoting cancer progression. SLC13 transporters can supply TCA intermediates that fuel biosynthetic pathways in tumor cells.
Neurodegeneration and Parkinson's disease
Dopamine-iron homeostasis interactions rescue mitochondrial fitness in Parkinson's disease models, highlighting the role of tricarboxylic acid transport in neuronal survival. SLC13A5 mutations cause early infantile epileptic encephalopathy, linking citrate transport to neurological function.
Cystic fibrosis and nephrolithiasis
Citrate transport is altered in cystic fibrosis, affecting CFTR function and increasing nephrolithiasis risk. Recovery of ΔF508-CFTR function by citrate suggests that modulating tricarboxylic acid transport can have therapeutic benefits.
Inflammatory diseases and immunometabolism
The IRG1-itaconate axis, which depends on TCA cycle intermediates, plays mechanistic roles in inflammatory diseases and offers therapeutic potential. Transport of itaconate precursors across membranes is critical for immunomodulation.
From tricarboxylic acid transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MPC1 impair pyruvate transport? | MPC1 knockout cell line |
| Does SLC13A5 mutation affect citrate transport? | SLC13A5 point mutation knock-in |
| Can citrate rescue ΔF508-CFTR function? | CFTR ΔF508 knock-in cells treated with citrate |
| Does TM4SF5 regulate mitochondrial-lysosome contact sites? | TM4SF5 overexpression and knockout |
| Does IRG1-itaconate axis modulate inflammation? | IRG1 knockout macrophages |
| Does dopamine-iron homeostasis affect mitochondrial fitness? | Dopamine receptor knockout neurons |
How to Study the tricarboxylic acid transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Metabolic flux analysis | Rate of substrate transport and metabolism | Quantifying TCA intermediate uptake |
| Cryo-EM | Structure and conformational states of transporters | Mechanistic studies of MPC |
| Live-cell imaging | Transport dynamics and organelle contact sites | Mitochondria-lysosome contact sites |
| CRISPR knockout screening | Genes required for transport | Functional genomics of metabolism |
| Proteomics | Protein expression and interactions | Transporter complex composition |
| RNA-seq | Transcriptional regulation of transporters | Metabolic state-dependent expression |
| Seahorse assay | Mitochondrial respiration and glycolysis | Functional impact of transport |
| Isotope tracing | Flux of labeled carbons through pathways | TCA cycle activity |
Metabolic flux analysis
Metabolic flux analysis using isotope-labeled substrates (e.g., 13C-pyruvate, 13C-citrate) measures the rate of tricarboxylic acid transport and subsequent metabolism. This method is essential for quantifying transport activity in cells and tissues.
Proteomics and structural biology
Proteomic profiling and structural studies, such as cryo-EM of the mitochondrial pyruvate carrier, reveal the molecular architecture and conformational changes of transporters during tricarboxylic acid transmembrane transport.
Live-cell imaging and organelle contact site analysis
Live-cell imaging with fluorescent reporters and organelle markers visualizes transport dynamics and mitochondria-lysosome contact sites. This approach has been used to study TM4SF5-enriched contact sites and cholesterol export.
CRISPR screening and functional genomics
CRISPR knockout and knock-in screens identify genes required for tricarboxylic acid transport and uncover synthetic lethal interactions. These methods are powerful for dissecting transporter function in disease models.
How CRISPR Can Be Used to Study GO:0035674 tricarboxylic acid transmembrane transport
Knockout
CRISPR knockout of transporter genes such as MPC1, MPC2, or SLC13A5 abolishes tricarboxylic acid transmembrane transport, enabling researchers to study the consequences for mitochondrial metabolism, cell growth, and disease phenotypes.
Point Mutation
Point mutation knock-in models, such as SLC13A5 mutations linked to epilepsy or CFTR ΔF508, allow precise interrogation of transport function and drug responses, including citrate rescue of CFTR function.
Knock-in
Knock-in of tagged transporters (e.g., GFP-MPC1) enables visualization and biochemical isolation of transport complexes, facilitating structural and dynamic studies of tricarboxylic acid transmembrane transport.
Overexpression
Overexpression of transporters such as TM4SF5 or SLC13A3 increases transport capacity and can drive metabolic reprogramming, providing models to study cancer and inflammatory diseases.
How EDITGENE Supports tricarboxylic acid transmembrane transport Research
Researchers studying tricarboxylic acid transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in substrate transport, metabolic reprogramming, or disease progression. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for tricarboxylic acid transmembrane transport research.
Frequently Asked Questions About tricarboxylic acid transmembrane transport
What is tricarboxylic acid transmembrane transport?
It is the biological process (GO:0035674) in which a tricarboxylic acid is transported across a membrane, as defined by the Gene Ontology.
What genes are involved in tricarboxylic acid transmembrane transport?
Key genes include MPC1, MPC2, SLC13A1-5, SLC25A1, SLC25A10, SLC25A11, TM4SF5, IRG1, and CFTR.
How is tricarboxylic acid transmembrane transport regulated?
It is regulated by cellular energy status, substrate availability, hormonal signals, and proteins such as TM4SF5 and IRG1.
What diseases are linked to tricarboxylic acid transmembrane transport?
Cancer, Parkinson's disease, cystic fibrosis, nephrolithiasis, epilepsy, and inflammatory diseases.
What is the role of the mitochondrial pyruvate carrier in this process?
The mitochondrial pyruvate carrier (MPC) mediates pyruvate transport into mitochondria, a key step in tricarboxylic acid transmembrane transport.
How do SLC13 transporters contribute to tricarboxylic acid transport?
SLC13 family transporters use sodium gradients to transport carboxylates such as citrate and succinate across membranes.
Can citrate rescue cystic fibrosis CFTR function?
Yes, citrate has been shown to recover ΔF508-CFTR function in cellular models.
What methods are used to study tricarboxylic acid transmembrane transport?
Metabolic flux analysis, cryo-EM, live-cell imaging, CRISPR screening, proteomics, and RNA-seq.
What CRISPR models are available for studying this process?
Knockout, point mutation, knock-in, and overexpression models for transporters and regulators.
Why is tricarboxylic acid transmembrane transport important for cancer?
It supports metabolic reprogramming and provides intermediates for biosynthesis, as seen with TM4SF5 and SLC13 transporters.
Conclusion
Tricarboxylic acid transmembrane transport (GO:0035674) is a fundamental biological process that governs the movement of TCA cycle intermediates across cellular membranes, impacting energy production, biosynthesis, and signaling. Its dysregulation is linked to cancer, neurodegeneration, cystic fibrosis, and inflammatory diseases. Understanding the molecular mechanisms and key transporters involved offers opportunities for therapeutic intervention. EDITGENE provides advanced CRISPR models and bioinformatics services to accelerate research in this field.
References
- 1. Kim JE et al.. 2024. Glucose-mediated mitochondrial reprogramming by cholesterol export at TM4SF5-enriched mitochondria-lysosome contact sites.. Cancer Commun (Lond) 44(1):47-75 PMID: 38133457
- 2. Buoso C et al.. 2024. Dopamine‑iron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease.. Neurobiol Dis 196:106506 PMID: 38648865
- 3. Gibney EM et al.. 2003. The association of nephrolithiasis with cystic fibrosis.. Am J Kidney Dis 42(1):1-11 PMID: 12830451
- 4. Liang J et al.. 2025. Structures and mechanism of the human mitochondrial pyruvate carrier.. Nature 641(8061):258-265 PMID: 40101766
- 5. Dimroth P et al.. 2008. ATP synthesis by decarboxylation phosphorylation.. Results Probl Cell Differ 45:153-84 PMID: 18049805
- 6. Borkenhagen B et al.. 2022. Recovery of ΔF508-CFTR Function by Citrate.. Nutrients 14(20) PMID: 36296967
- 7. Liu Y et al.. 2026. IRG1-itaconate axis in immunometabolism: mechanistic roles and therapeutic potential in inflammatory diseases.. Front Immunol 17:1767601 PMID: 41743716
- 8. Li P et al.. 2026. SLC13 sodium-carboxylate transporters: function, regulation and pathophysiological implications in human disease.. Biochem Pharmacol 246:117744 PMID: 41581574
